In fact, there has been a large number of studies about the possible role of Type2 biomarkers in COPD in the last few years, so that the prevalence and meaning of existent Type2 biomarkers such as sputum and blood eosinophils, exhaled nitric oxide fraction (FeNO), immunoglobulin E (IgE), and atopy have attracted attention in patients with COPD. This evidence concerns the gene IGHE and chronic obstructive pulmonary disease.